The test battery approach gives the opportunity to qualify this new group of compounds by non-tiered testing in multiple assays covering different key biological processes.
As described in that introductory paper, the Key Events Dose-Response Framework is based on the premise that for any given bioactive agent, chemical, allergen, pathogen, etc., there are multiple "key events" along the biological pathway from initial intake to the ultimate effect of concern.
Gα·GTP and Gβγ subunits regulate the activity of target effector proteins such as adenylyl cyclases, phospholipase C isoforms, ion channels, and phosphodiesterases, which in turn regulate multiple downstream signaling cascades that initiate key biological processes such as development, vision, olfaction, cardiac contractility, and neurotransmission [1] [3].
These overall findings support the idea of multiple parallel processes involved in perturbing key biological pathways or networks in the pathogenesis of ILD.
A majority of mammalian protein-coding genes are conserved targets of miRNA regulation, and each miRNA has multiple mRNA targets [ 3]. miRNAs regulate key biological and pathological processes such as differentiation, cell signaling, tumorigenesis, and various disease states [ 4- 11].
Exciting new approaches utilizing mass spectrometry-based neuropeptidomics (18– 22) to simultaneously identify neuropeptide profiles in a single biological event will open our understanding of how multiple neuropeptides, rather than a single neuropeptide, are cosecreted for coregulation of key biological functions.
A wealth of experimental data from lower organism studies supports this concept, and human progeroid syndromes indicate that disruption of key biological processes can result in the premature onset of multiple age-related pathologies (Ghosh & Zhou, 2014).
Multiple variations are possible in the innate immunity framework presented here, while preserving the three key biological features of the model.
Furthermore, these factors differentiate key biological phenotypes in breast cancer, are able to improve clinical predictions across multiple cancer data sets, and retain their predictive ability even when applied to samples taken at vastly different times or at different study centers.
The lab can also do DNA fingerprinting to identify the pathogen for key biological weapons.
